Canada Markets closed

Small Pharma Inc. (DMTTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1946-0.0143 (-6.85%)
At close: 03:56PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.2089
Open0.2410
BidN/A x N/A
AskN/A x N/A
Day's Range0.1873 - 0.2410
52 Week Range0.0600 - 0.9700
Volume89,602
Avg. Volume121,687
Market Cap61.844M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Small Pharma to Attend Upcoming Healthcare Conferences in January 2022

    LONDON, United Kingdom, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its attendance at the 11th Annual LifeSci Partners Annual Corporate Access Event, and the H.C. Wainwright Bioconnect Conference, from January 5-7, 2022, and January 10-13, 2022, respectively. 11th Annual LifeSci Partners Corporate Access Event (January 5-7, 2022)Sma

  • GlobeNewswire

    Small Pharma to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6, 2021

    LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces its participation in the H.C. Wainwright 2nd Annual Psychedelics Conference, which is being held virtually on Monday, December 6, 2021. A webcast presentation hosted by Peter Rands, Small Pharma’s Chief Executive Officer, will be available to view on demand beginning on December 6, 2021 at 7:00

  • GlobeNewswire

    Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

    LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a non-executive independent director of the board of directors of the Company (the “Board”). He will hold office as an independent director until the next annual meeting of shareholders, or until his successor has been elected or appointed. Mr. Maier ha